ABSTRACT
INTRODUCTION

63
In 1899, cancer researcher D'Arcy Power noted: "Where malaria is common, cancer is rare." [1] 64 For centuries, physicians have observed that acute infection can be associated with spontaneous 65 cancer regression, and it is now well appreciated that the potent immune response to the threat of 66 acute infection can overcome malignancy [2, 3] . One of the best known early clinical applications of the anti-cancer immunological response induced by acute infection [5, 6] . This new deeper 81 appreciation of innate immune system adaptation and reprogramming is projected to meaningfully 82 advance the use of microbial-based treatments for not only cancer, but also for many of the 83 increasingly prevalent immune-based diseases we now contend with, including inflammatory 84 bowel disease, allergies and autoimmune disorders [5] [6] [7] .
85
We recently characterized the key immune cellular and molecular pathways by which mimicking 86 an acute infection using a microbe-based stimulus markedly reduces the tumor burden in two 87 different lung cancer models [8] . The treatment used was formulated from an inactivated lung 88 pathogen, a derivative of a clinical isolate of Klebsiella, which is subcutaneously administered 89 every second day [8] . Efficacy in reducing lung tumor burden was shown to be 1) dependent on 90 the animals having had previous exposure to Klebsiella and 2) independent of adaptive immunity 91 [8] . In the work presented here, we describe a newly discovered phenomenon of organ-specific 92 trained innate immune cell recruitment and disease amelioration. We show organ specificity is 93 determined by the organ niche of the bacterial species from which the microbial stimulant is 94 derived. These findings suggest that there are levels of greater complexity of innate immune observed that mice without prior lung exposure to Klebsiella did not experience a reduction in 105 tumor burden with QBKPN treatment, whereas mice with prior exposure to Klebsiella did [8] .
106
Here we show that when we administer a similarly formulated immunotherapy based on 6 107 Escherichia coli, called QBECO, there is little relative efficacy in reducing lung cancer burden in 108 the Lewis Lung Carcinoma model, despite all animals likely having exposure to E. coli (Fig. 1A) .
109
We replicated the previous findings in a different lung cancer model using B16F10 melanoma cells 110 (Supplemental Fig. 1A) , which suggests QBKPN's anti-cancer efficacy is not cancer cell type 111 specific, rather it appears to be applicable to different cancer cell types growing in the lungs. We 112 hypothesized that QBECO may have a therapeutic anti-tumor effect in a compartment likely to be 113 exposed to E. coli. We first used an intraperitoneal cancer model since E. coli infection is the most 114 common cause of Gram-negative peritonitis [9] . MC-38 adenocarcinoma cells were administered 115 by intraperitoneal injection to establish the cancer [10] . In this model every second day 116 subcutaneous administration of QBECO significantly increased survival compared to vehicle 117 treatment; whereas, QBKPN treatment was less efficacious (Fig. 1B) . QBECO treatment also 118 improved survival when pancreatic cancer cells were seeded intraperitoneally (Supplemental Fig.   119 1B). Thus, QBECO treatment improved survival in animals with cancer in the peritoneal region 120 independent of cancer cell type, corroborating the analogous observation with respect to QBKPN's 121 anti-cancer efficacy in the lungs. Collectively, these findings suggest there are organ-specific 122 immune effects of these microbial treatments and that these subcutaneously administered products 123 are sampled by immune cells in the targeted organ niche. To exclude the possibility that the 124 efficacy of these microbial-based treatments was a result solely of reduced seeding of injected 125 cancer cells, we tested both QBKPN and QBECO in a chemically-induced colon cancer model in 126 which cancer develops with exposure to DSS/AOM over a 70 day period [11, 12] . Because both
127
Klebsiella species and E. coli are enteric bacteria in mice, both QBKPN and QBECO treatment 128 succeeded in reducing tumor burden in the colon compared to vehicle-treated mice in this model 129 (Fig. 1C) . A biodistribution study using in vivo imaging of fluorescently labelled QBKPN (Cy5. 5-7 130 QBKPN) confirmed that the product is systemically distributed (Supplemental Fig. 2A) Fig. 2A-B) .
141
To account for the greater recruitment of NK cells and macrophages to the lungs by QBKPN vs.
142
QBECO treatment, lung chemokine concentrations were quantified. Relative to both vehicle 143 control and QBECO, treatment with QBKPN led to higher levels of chemokines important for the 144 recruitment and activation of NK cells and macrophages, including CCL2, CCL5, and IFNγ-145 inducible chemokines, CXCL9 and CXCL10, at both 5 and 17 days following tumor inoculation 146 (Fig. 2C) . IFNγ gene expression was increased with QBKPN treatment compared to QBECO at 147 both timepoints measured (Fig. 2D) ; however, protein levels of IFNγ were measurably greater at 148 only the day 5 timepoint (Supplemental Fig. 3 ). QBKPN's anti-lung cancer efficacy was 149 previously found to be dependent on the activation of the NKG2D pathway, which is fundamental (Fig. 3A) . In parallel, QBKPN 8 153 treatment led to a more potent induction of molecules that mediate anti-tumor cytotoxicity 154 including, Granzyme A (GzmA), Granzyme B (GzmB) and Perforin 1 (Pfr1), in the lungs of mice 155 with cancer ( Fig. 3B-E ).
156
The lung-specific immune response elicited by QBKPN is enhanced by the presence of 157 pathology
158
The contribution of the presence of a lung pathology to the type and extent of the immune response 159 triggered by QBKPN vs. QBECO was investigated using cancer-free mice. Among the most 160 notable differences in the immune response in healthy animals was the proportion of NK cells 161 recruited to the lungs with QBKPN treatment, which was markedly attenuated in healthy mice 162 compared to lung cancer bearing mice (Fig. 4A vs. Fig. 2A ). In contrast, the proportion of 163 interstitial macrophages increased in both healthy mice and mice with cancer (Fig. 4B, Fig. 2B ).
164
Another difference in healthy vs. lung cancer bearing mice was the degree to which certain immune 165 responses were sustained. In particular, the expression of IFNγ and Rae1, which decreased or 166 remained the same over time in healthy mice (Fig. 4) , increased over time in cancer-bearing mice 167 (Fig. 3) . However, similar to cancer-bearing mice, there was greater lung immune stimulation with 168 QBKPN than with QBECO treatment, but this difference was generally less pronounced in healthy 169 mice. The exception to this observation was in the gene expression, but not protein levels, of 170 granzyme B, granzyme A, and perforin, which showed equal increases with 27 days of either 171 QBKPN or QBECO treatment in disease-free animals (Fig. 4G) . Collectively, these findings 172 suggest that the presence of pathology dictates the extent, duration and type of lung-specific Kit + Sca + (LSK + ) ( Fig. 5D-E) . In particular, both microbial products increased the production of diseases growing in incidence and prevalence [5, 24, 25] . In this work, we describe what we believe 266 to be a seemingly unknown phenomenon of the existence of immunological memory contained 267 within specific regional niches for microbes that normally inhabit or infect it. We were able to arm of the immune system, and 2) innate immunity lacks specific memory [5, 6, 26, 27] . The 284 treatment strategy we employed is rooted in both the trainability of the innate immune system and 285 its more nuanced organ specificity, which is intrinsically different from that of the adaptive 286 immune system [26] . We demonstrated that subcutaneous administration of our microbial-based by which this microbial regulation is instituted was not defined.
317
It makes intuitive sense that there exists a means by which the innate immune system directs its 318 resources to the most likely source of infection upon detecting microbial components that are 319 presented as an acute threat. We propose this organ-specific microbial recognition reflects a more 
MATERIALS AND METHODS
352
Animals
353
Female C57BL/6J mice (aged 6-10 weeks) were sourced from Jackson Laboratories (Bar Harbor, 354 ME, USA) and Envigo (Livermore, CA, USA). Female CCR2-deficient mice (B6.129S4- 
406
For the skin cancer study, B16-F10 cells were injected subcutaneously at 1 x 10 5 cells in 100 µL 407 PBS. Tumor length, width, and height were measured by digital calipers and the tumor burden was 408 calculated using these measurements every second day.
409
DSS/AOM model
410
Mice were injected intraperitoneally on day 0 with azoxymethane (AOM; Sigma, Kawasaki,
411
Kanagawa Prefecture, Japan), at 8 mg/kg body weight, 10 days after treatment started. After AOM 
418
Labelling of the microbial-based product, QBKPN, was carried out using Cy5.5 NHSester (GE
419
Healthcare Life Sciences). All optical imaging experiments were performed using a small-animal 
450
Gene expression
451
The right lung post-caval lobe was homogenized by a TissueLyser LT (Qiagen, Toronto, ON, 452 Canada). RNA was isolated using the PureLink RNA Mini Kit (Life Technologies, Carlsbad, CA, 453 USA) and reverse transcribed into cDNA using the iScript cDNA Synthesis Kit (Bio-Rad). Gene 
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For each experiment, mice were given the designated treatment by subcutaneous injection every 640 second day starting 10 days before tumor seeding and continuing throughout the experiment. Data 641 is presented as the mean ± SD. * p < 0.05; ** p < 0.01; **** p < 0.0001, one-way ANOVA with 642 Holm-Sidak's and Log-rank test. for CXCL9, CXCL10, CCL2 and CCL5 in cancer free mice after 27 days of Vehicle, QBKPN and 
